HOTH Overview

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).

Wall Street analysts forecast HOTH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOTH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Hoth Therapeutics Inc revenue for the last quarter amounts to -4.08M USD, increased 83.05

Hoth Therapeutics Inc. EPS for the last quarter amounts to -2792672.00 USD, decreased

Hoth Therapeutics Inc (HOTH) has 2 emplpoyees as of March 12 2026.

Today HOTH has the market capitalization of 17.69M USD.